Propanc Biopharma Files 8-K: Material Agreement & Equity Sales
Ticker: PPCB · Form: 8-K · Filed: Jun 5, 2024 · CIK: 1517681
| Field | Detail |
|---|---|
| Company | Propanc Biopharma, Inc. (PPCB) |
| Form Type | 8-K |
| Filed Date | Jun 5, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $49,200, $41,000, $49,200.00, $7,380.00, $28,290 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation, equity-sale
TL;DR
Propanc Biopharma inked a deal, sold stock, and took on debt on May 31st. Big moves.
AI Summary
Propanc Biopharma, Inc. entered into a material definitive agreement on May 31, 2024. The company also created a direct financial obligation and reported unregistered sales of equity securities. The filing includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate actions, including new agreements and the issuance of equity, which could impact the company's financial structure and shareholder value.
Risk Assessment
Risk Level: medium — The filing details material definitive agreements, financial obligations, and unregistered equity sales, which can introduce financial and operational risks.
Key Players & Entities
- Propanc Biopharma, Inc. (company) — Registrant
- May 31, 2024 (date) — Date of earliest event reported
FAQ
What type of material definitive agreement did Propanc Biopharma enter into?
The filing states that Propanc Biopharma, Inc. entered into a material definitive agreement on May 31, 2024, but does not specify the nature of the agreement in the provided text.
What is the significance of the 'Creation of a Direct Financial Obligation' item?
This item indicates that Propanc Biopharma, Inc. has incurred a direct financial obligation, which could involve debt or other financial commitments.
What does 'Unregistered Sales of Equity Securities' imply for Propanc Biopharma?
This suggests that Propanc Biopharma, Inc. has sold equity securities that were not registered with the SEC, which may have specific disclosure requirements and implications for investors.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on May 31, 2024.
What is the state of incorporation for Propanc Biopharma, Inc.?
Propanc Biopharma, Inc. is incorporated in Delaware.
Filing Stats: 976 words · 4 min read · ~3 pages · Grade level 11.6 · Accepted 2024-06-05 06:05:29
Key Financial Figures
- $49,200 — ny in the aggregate principal amount of $49,200 (the "Note"), for a purchase price of $
- $41,000 — 0 (the "Note"), for a purchase price of $41,000. The Company intends to use the net pro
- $49,200.00 — on the Issuance Date to the Principal ($49,200.00 * fifteen percent (15%) = $7,380.00). A
- $7,380.00 — l ($49,200.00 * fifteen percent (15%) = $7,380.00). Accrued, unpaid interest and outstand
- $28,290 — with the first on November 30, 2024 for $28,290.00, and the other four payments on Dece
- $56,580.00 — 72.50 (a total payback to the Holder of $56,580.00). The Company shall have a five (5) day
Filing Documents
- form8-k.htm (8-K) — 41KB
- ex4-1.htm (EX-4.1) — 96KB
- ex10-1.htm (EX-10.1) — 82KB
- 0001493152-24-022624.txt ( ) — 422KB
- ppcb-20240531.xsd (EX-101.SCH) — 3KB
- ppcb-20240531_lab.xml (EX-101.LAB) — 33KB
- ppcb-20240531_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 4, 2024 PROPANC BIOPHARMA, INC. By: /s/ James Nathanielsz Name: James Nathanielsz Title: Chief Executive Officer and Chief Financial Officer